GHK-Cu
In a topical trial with 13 people, GHK-Cu users said their skin improved more than controls (PMID 16847171; p = 0.04; checked 24 Aug 2026). Blinded raters and software found no group difference. PubMed names no funder. The study did not inject GHK-Cu. No finished human injection trial was found.
Which names and identifiers belong to GHK-Cu?
GSRS gives the names GHK COPPER, COPPER TRIPEPTIDE-1, and PREZATIDE COPPER (GSRS; checked 24 Aug 2026). It gives UNII 6BJQ43T1I9 and CAS 89030-95-5.
The complex joins copper(II) to glycyl-L-histidyl-L-lysine. It is not AHK-Cu or a peptide with a fat chain.
What did the completed topical trial measure?
Thirteen people finished the trial after a random draw (PMID 16847171; checked 24 Aug 2026).
| Measure | Finding | Route | Source |
|---|---|---|---|
| Patient-rated overall skin quality | Favoured GHK-Cu; p = .04 | Topical | PMID 16847171 |
| Earlier redness resolution | No significant group difference | Topical | PMID 16847171 |
| Wrinkles and overall skin quality | No objective group difference | Topical | PMID 16847171 |
The abstract has no table of adverse events. PubMed marks support from a non-US public body but names no agency. Full-paper funding was not checked.
What topical human study is recruiting now?
NCT07437586 is a blind Phase 2 skin-gel study with a random draw (ClinicalTrials.gov; checked 24 Aug 2026). It plans 60 healthy adults. Hudson Biotech pays for it. No results are posted.
What human injectable evidence is available?
Exact PubMed and ClinicalTrials.gov searches found no finished human GHK-Cu injection trial (checked 24 Aug 2026). The US FDA treats injection and skin use as two routes. It says human injection safety data are limited (US FDA; checked 24 Aug 2026).
The skin result does not show an injected effect or injected safety.
What did the large vial dataset report?
A 2026 preprint studied 6,441 user-sent samples across 14 compounds, including GHK-Cu (DOI 10.20944/preprints202604.1748.v1; checked 24 Aug 2026). Median GHK-Cu purity was 99.90%. The report does not give the GHK-Cu sample count.
The work was not peer reviewed. It used a public test set, not samples bought by the authors. It does not show sterility or the amount in a reader's vial.
What does evidence tier B mean here?
Tier B comes from a small human skin study with a random draw (checked 24 Aug 2026). It gives no human evidence for injection. Public status and evidence tier stay apart.
What is the recorded EU status?
The EU Commission index has no exact entry for GHK-Cu or Copper tripeptide-1 (Union Register index; checked 24 Aug 2026). The EU field stays unclear.
When was injectable GHK-Cu first observed in a product dataset?
The preprint came out in April 2026 and names GHK-Cu in the test set. It supports 2026-04 as a publication by-date, not the sample month (checked 24 Aug 2026).
What does this register entry cover?
This entry keeps skin evidence, the injection gap, and vial data apart. No full guide is live yet.